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Abstract
Introduction
MLL-rearranged acute lymphoblastic leukemia (ALL) in infants (<1 year) is characterized
by high relapse rates and a dismal prognosis. To facilitate the discovery of novel therapeutic
targets, we here searched for genes directly influenced by the repression of various
MLL fusions.
Methods
For this, we performed gene expression profiling after siRNA-mediated repression ofMLL-
AF4,MLL-ENL, and AF4-MLL inMLL-rearranged ALL cell line models. The obtained results
were compared with various already established gene signatures including those consisting
of known MLL-AF4 target genes, or those associated with primaryMLL-rearranged infant
ALL samples.
Results
Genes that were down-regulated in response to the repression ofMLL-AF4 andMLL-ENL
appeared characteristically expressed in primaryMLL-rearranged infant ALL samples, and
often represented knownMLL-AF4 targets genes. Genes that were up-regulated in re-
sponse to the repression ofMLL-AF4 andMLL-ENL often represented genes typically si-
lenced by promoter hypermethylation inMLL-rearranged infant ALL. Genes that were
affected in response to the repression of AF4-MLL showed significant enrichment in gene
expression profiles associated with AF4-MLL expressing t(4;11)+ infant ALL patient
samples.
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Conclusion
We conclude that the here identified genes readily responsive to the loss ofMLL fusion ex-
pression potentially represent attractive therapeutic targets and may provide additional in-
sights inMLL-rearranged acute leukemias.
Introduction
A hallmark of acute lymphoblastic leukemia (ALL) in infants (<1 year of age) is a high inci-
dence (*80%) of chromosomal translocations involving theMixed Lineage Leukemia (MLL)
gene [1, 2], in which the N-terminal portion ofMLL fuses to the C-terminal region of one of its
many translocation partner genes. [3] The most commonMLL translocations found among in-
fant ALL patients are t(4;11), t(11;19), and t(9;11), fusingMLL to AF4, ENL and AF9, respec-
tively. [2, 4]MLL-rearranged infant ALL is associated with an adverse outcome, with event-
free survival rates of only*30–40%. [2]
MLL-rearranged ALL cells display unique gene expression profiles, consisting of over-
whelming numbers of differentially transcribed genes [5, 6], which make it difficult to distin-
guish between the actual “drivers” of the leukemia from the so called “bystanders”. Fortunately,
recent advances allowed the identification of genes likely to be activated by MLL fusion pro-
teins via the recruitment of DOT1L. [7–9] Yet, apart from MLL fusion driven activation of
gene transcription, inactivation of transcription also plays an important role inMLL-rear-
ranged ALL. We and others, recently demonstrated thatMLL-rearranged infant ALL is charac-
terized by unique patterns of gene promoter DNA hypermethylation, leading to transcriptional
silencing of associated genes. [10, 11] To make matters even more complicated, more than half
of the t(4;11)-positive ALL patients not only carry theMLL-AF4 fusion transcript, but also ex-
press and translate the reciprocal AF4-MLL transcript, which has been proposed to substantial-
ly contribute, or even being essential, for leukemia development.[12, 13]
Here, we studied the direct transcriptional consequences of the loss of MLL fusion tran-
scripts in order to identify potential target genes for therapeutic intervention. For this, we per-
formed gene expression profiling inMLL-rearranged ALL cell line models in whichMLL-AF4,
AF4-MLL orMLL-ENL expression was repressed by siRNA-mediated RNA interference. We
postulate that genes directly responding to the loss of the MLL fusion represent important ther-
apeutic targets and may provide additional insights into the actions of MLL fusion proteins.
Methods
Note: More detailed descriptions of all experimental procedures and data analysis methods can
be found in the Supplemental Materials (S1 File).
Cell line models
The B-ALL cell lines RS4;11 and SEMK2 both carry translocation t(4;11) generating the
MLL-AF4 and AF4-MLL fusion transcripts. KOPN-8 carries a t(11;19) translocation generating
MLL-ENL transcripts. RS4;11 was established from the bone marrow of a 32-year-old woman
[14], and was purchased from the German Collection of Microorganisms and Cell Cultures
(DSMZ). SEMK2 is a subclone of the SEM cell line, which was originally derived from a 5-
year-old girl at relapse [15] and was kindly provided by Dr Scott Armstrong (Memorial Sloan
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Kettering Cancer Center, New York, USA). KOPN-8 was derived from a 3-month-old infant
girl with B-cell precursor ALL and was purchased from DSMZ.[16]
siRNA-mediated RNA interference
Cells were transfected with siRNAs directed againstMLL-AF4 [17], AF4-MLL [13], orMLL-ENL
(sense 5’-CCAAAAGAAAAGUCUGCCCAG-3; antisense 5’-CUGGGCAGACUUUUCUUUU
GGUU-3’), using electroporation. Control cells were transfected with siRNAs againstAML1-MTG8
(AGF1) [18], a fusion transcript absent in both SEMK2 and RS4;11 cells. For the knock-down of
MLL-AF4 andMLL-ENL, cells were harvested after two days. For the AF4-MLL knock-down, cells
were transfected with siRNAs a second time after two days of culturing, and eventually harvested
at day 4. All experiments were performed at least three times.
RNA extraction
Total RNA was extracted from a minimum of 2x106 cells using TRIzol reagent (Invitrogen,
Life Technologies, Breda, The Netherlands) according to manufacturer’s guidelines.
Gene expression profiling
Gene expression profiling was performed using HU133plus2.0 microarrays (Affymetrix) ac-
cording to manufacturer’s guidelines. Gene expression profiles for the primary infant ALL
patients samples were generated and published previously [19].
Results
Transcriptional consequences of MLL fusion knock-down
Compared to cells transfected with control siRNAs,MLL-AF4mRNA expression was reduced
to 45% and 37% in the t(4;11)-positive ALL cell lines RS4;11 and SEMK2, respectively, upon
transfection with siRNAs directed againstMLL-AF4. Using siRNAs directed againstMLL-ENL,
the level ofMLL-ENL expression in KOPN-8 cells was reduced to 5% (Fig. 1A). Western blot
analysis demonstrated a reduction of the MLL-AF4 protein expression (relative to control
cells) of 28% and 52% in RS4;11 and SEMK2 cells, respectively (Fig. 1B).
Next, in order to identify genes directly responding to the loss of the MLL fusion, we gener-
ated gene expression profiles (HU133plus2.0 GeneChips, Affymetrix) in three independent ex-
periments. Upon repression ofMLL-ENL in KOPN-8 cells, significant differential expression
was observed for 342 probe sets (p<0.001). Reduced expression ofMLL-AF4 resulted in signifi-
cantly (p<0.001) altered expression of 26 probe sets in RS4;11 cells, and 145 probe sets in
SEMK2 cells. Fig. 2A shows heatmaps displaying the most significantly altered probe sets for
all three cell lines.
We searched for a core signature of genes consistently affected inall cell lines by performing
a paired analysis of all samples in which the MLL fusion was suppressed (including SEMK2,
RS4;11, and KOPN8), compared to all control samples, including cells transduced with control
siRNAs directed against AML1-MTG8 (AFG1), as well as control cells electroporated in the ab-
sence of siRNAs. Compared to cells transfected with control siRNAs, 101 probe sets appeared
to be recurrently affected in all cell lines. Compared to cells only subjected to electroporation in
the absence of siRNAs (i.e. pulse control), 86 probe sets were differentially expressed. Merging
these analyses, we found 56 overlapping probe sets to be recurrently differentially expressed in
all cell lines in which the MLL fusions were suppressed (Fig. 2B). Hierarchical clustering analy-
sis showed that these 56 probe sets effectively distinguished between cells in which the MLL fu-
sion was knocked down and control samples, as separately shown for each cell line (Fig. 2C).
MLL Fusion Knockdown Gene Expression Profiling
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As these probe sets consistently responded to the loss of the MLL fusion, we postulate that this
gene signature represents genes which are highly dependent on the presence of the MLL fusion,
and as such may exert prominent functions in MLL fusion driven transformation. Probe set
IDs, HGNC gene symbols, and log-fold changes of the obtained core signature consisting of
the 56 probe sets are listed in the supplemental (S1 and S2 Tables). HGNC gene symbols from
these 56 probe sets can also be found next to the heatmap in Fig. 3.
Relevance of the MLL fusion knock-down signature
To explore the relevance of the obtained gene signature consisting of 56 probe sets responsive
to the knock-down of the MLL fusion, we compared our signature to that of earlier published
gene sets associated withMLL-rearranged ALL. The first signature, published by Guenther
et al [8], contains 42 genes occupied by the MLL-AF4 fusion protein. The second gene set pub-
lished by Krivtsov et al [7] consists of genes associated with MLL fusion mediated H3K79
dimethylation. Gene set enrichment analysis (GSEA) showed significant enrichment of these
genes in our MLL fusion knock-down gene signature (normalized enrichment scores (NES) of
1.92 and 2.11 respectively; leading edge in S3 Table and S4 Table respectively) (Fig. 3). These
Fig 1. siRNA-mediated knock-down significantly decreases MLL fusion expression levels. (A) mRNA expression levels ofMLL-ENL (grey), wild-type
MLL (white), and wild-type ENL (black) in KOPN-8 cells, orMLL-AF4 (grey), wild-typeMLL (white) and wild-type AF4 (black) in RS4;11 and SEMK2 cells
after transfection with active siRNA directed against the absent target AML1/MTG8 (siAGF1), empty pulse (no siRNAs), and siRNAs directed against
MLL-ENL andMLL-AF4 respectively. Shown is the average mRNA expression of two experiments ± standard error of the mean. (B) Protein expression
levels of MLL-AF4 in RS4;11 and SEMK2 shown by western blot (left panel). The western blot was probed with antibodies against the N-terminus of MLL to
detect MLL-AF4. Clathrin was used as a loading control. The graph (right panel) shows western blot quantification of MLL-AF4 protein expression relative to
clathrin with the empty pulse control set at 100%.
doi:10.1371/journal.pone.0120326.g001
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PLOS ONE | DOI:10.1371/journal.pone.0120326 March 20, 2015 4 / 16
Fig 2. Differential gene expression in response to the repression of MLL-AF4 and MLL-ENL. (A)
Heatmap visualization of gene expression profiles (Affymetrix HGU133plus2.0 GeneChips) of the top 50
most differentially expressed genes in response toMLL-ENL knock-down in KOPN-8 cells, andMLL-AF4
knock-down in RS4;11 and SEMK2 cells, as compared to control cells transfected with siAGF1 or
electroporated in the absence of siRNAs (pulse control). The presented data was derived from samples
obtained from three independent experiments. Red depicts high expression, blue depicts low expression. (B)
Venn diagram showing the number of differentially expressed genes (p<0.001) in KOPN-8, RS4;11, and
SEMK2 cells transfected with siRNAs againstMLL-ENL andMLL-AF4, combined (MLL fusion knock-down,
n = 9) versus control cells transfected with siAGF1 (AGF1 control, n = 9), versus control cells electroporated
in the absence of siRNAs (pulse control n = 9). All probe sets and gene symbols are listed in S1 and S2
Tables. (C) Hierarchical clustering based on 56 differentially expressed probe sets recurrently affected in
both KOPN-8, RS4;11, and SEMK2 cells uponMLL fusion knock-down (light grey), in control samples
transfected with siAGF1 (dark grey), and control samples electroporated in the absence of siRNAs (black).
doi:10.1371/journal.pone.0120326.g002
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Fig 3. Genes responsive to the repression of MLL-ENL andMLL-AF4 often represent knownMLL-AF4
target genes.Gene set enrichment analysis (GSEA) of the 56 differentially expressed probe sets recurrently
MLL Fusion Knockdown Gene Expression Profiling
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data indicate that some, but not all, genes transcriptionally activated by the MLL fusion gene it-
self, rapidly respond to the loss of the MLL fusion.
Moreover, using our core signature consisting of 56 probe sets associated with knock-down
of the MLL fusion, we performed hierarchical clustering on gene expression profiling data gener-
ated on a large cohort of primaryMLL-rearranged infant ALL (n = 71), wild-typeMLL pediatric
precursor B-ALL (n = 16), and wild-typeMLL infant ALL (n = 20) samples, as well as healthy
bone marrow samples (n = 13) as non-leukemic controls. Based on these 56 probe sets,MLL-re-
arranged ALL samples could almost be flawlessly separated from ALL samples with wild-type
MLL genes (Fig. 4A). These data imply that our MLL fusion knock-down signature represents
genes highly characteristic forMLL-rearranged ALL. Similarly, gene set enrichment analysis
(GSEA) showed strong enrichment in theMLL-rearranged patients of the 57 probe sets that are
significantly lower expressed after MLL fusion knock-down (NES = 1.95, p = 0.002) (Fig. 4B,
dataset in S5 Table; leading edge in S6 Table).
Pathway analysis using the database for annotation, visualization, and integrated discovery
(DAVID) demonstrated a significant number of genes transcriptionally responsive to the loss
of MLL fusion expression to be involved in the KEGG focal adhesion pathway (hsa04510,
p<0.0001) and the KEGG small cell lung cancer pathway (hsa05222, p = 0.008). Next, we used
Ingenuity pathway analysis (IPA) to explore possible upstream regulators of the genes down-
regulated upon the loss of MLL fusion expression. This revealed 30 potential regulators includ-
ing 5 genes (i.e. HOXA7, LIN28B, UPF1, EZH2, andMBD1), and 25 miRNAs (see S7 Table).
Interestingly, the majority (i.e. 17 out of the 25) of the miRNAs that potentially regulate the
genes down-regulated uponMLL fusion knock-down, are predicted to target eitherMLL (i.e.
KMT2A) or AF4 (i.e. AFF1), or both. Hence, the genes observed to be transcriptionally respon-
sive to the loss ofMLL fusions, likely represent genes controlled by the MLL fusion itself.
Transcriptional consequences of AF4-MLL knock-down
Using siRNAs directed against AF4-MLL previously reported by Kumar et al. [13], we managed
to reduce expression of AF4-MLLmRNA to*40% in RS4;11 and*53% in SEMK2 cells, as
compared with cells transfected with control siRNAs (Fig. 5A). In these experiments, the ex-
pression of wild-type AF4 was not affected. However, despite numerous attempts, we were not
able to prevent reduction of wild-typeMLL expression to comparable levels of that of the AF4-
MLL transcript (Fig. 5A). Paired differential gene expression analysis between samples with a
knock-down of AF4-MLL (n = 6) and samples transfected with control siRNAs (n = 6) revealed
80 differentially expressed probe sets (p<0.001). The same analysis comparing AF4-MLL
knock-down samples with control cells electroporated in the absence of siRNAs (i.e. pulse con-
trol) (n = 6), revealed 58 differentially expressed probe sets. A total of 36 overlapping probe
sets (corresponding to 22 genes) were differentially expressed in both comparisons (Fig. 5B).
Probe set IDs, HGNC gene symbols, log-fold changes and p-values are listed in S8 Table and
S9 Table. Based on these 36 probe sets, hierarchical clustering could effectively separate AF4-
MLL knock-down samples from control samples (Fig. 5C).
To validate the AF4-MLL knock-down signature, we compared our signature to a gene set pub-
lished by Gaussmann et al consisting of AF4-MLL fusion target genes, [20] GSEA showed a signif-
icant enrichment of these AF4-MLL target genes in our AF4-MLL gene signature (NES = 1.68,
p = 0.002) (Fig. 5D).
affected in both KOPN-8, RS4;11, and SEMK2 cells uponMLL fusion knock-down in gene lists consisting of
MLL-AF4 target genes as published by Guenther et al. (8) (left) and Krivtsov et al. (7) (right).
NES = normalized enrichment score.
doi:10.1371/journal.pone.0120326.g003
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Using our previously published gene expression profiling data, we compared t(4;11)-posi-
tive infant ALL samples which do and do not express the reciprocal AF4-MLL fusion product,
as determined by PCR analysis. This comparison revealed 403 probe sets differentially express-
ed between both patient groups (p = 0.01). Fig. 6A shows a heatmap of the top 50 most signifi-
cant differenitially expressed probe sets. Based on these 50 probe sets, principal component
analysis (PCA) showed a clear separation of both patient groups (Fig. 6B). Furthermore, we ob-
served that the gene expression patterns of patients expressing the AF4-MLL fusion transcript
were enriched for genes that were down-regulated after knock-down of the AF4-MLL in the
cell line models RS4;11 and SEMK2 (GSEA; NES = 1.67, p = 0.02; leading edge in S12 Table)
Fig 4. Genes responsive to the repression of MLL-ENL andMLL-AF4 accurately characterize primary
MLL-rearranged infant ALL samples. (A) Heatmap visualization and hierarchical clustering of primaryMLL-
rearranged infant ALL samples (MLL-r, red, n = 71), wild-typeMLL pediatric ALL samples (both infants
(n = 20) and children>1 year of age (n = 16)) (wtMLL, blue, n = 36), and whole bone marrow samples
derived from healthy children (healthy BM, dark blue, n = 13) based on the 56 differentially expressed probe
sets recurrently affected in both KOPN-8, RS4;11, and SEMK2 cells uponMLL fusion knock-down. Up-
regulated genes are depicted in red, down-regulated genes are depicted in blue. (B) Gene set enrichment
analysis (GSEA) of the 57 probe sets that are significantly lower expressed upon knock-down of theMLL
fusion in gene expression profiles ofMLL-rearranged patients. Probe sets and HGNCGene Symbols of the
gene set are listed in S5 Table.
doi:10.1371/journal.pone.0120326.g004
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Fig 5. Differential gene expression in response to the repression of AF4-MLL. (A) mRNA expression
levels of AF4-MLL (grey), wild-typeMLL (white), and wild-type AF4 (black) in RS4;11 and SEMK2 cells after
transfection with siRNAs directed against AF4-MLL, siRNAs against the leukemic fusion gene AML1/MTG8
(siAGF1), or cells electroporated in the absence of siRNAs (pulse control). The average mRNA expression
relative to the siAGF1 controls of two independent experiments ± standard error of the mean is shown. (B)
Venn diagram showing the number of differentially expressed genes (p<0.001) in RS4;11 and SEMK2 cells
in which AF4-MLL was repressed (AF4-MLL knock-down, n = 6), versus cells transfected with control siRNA
(siAGF1 control, n = 6), and cells electroporated in the absence of siRNAs (pulse control, n = 6). (C)
Hierarchical clustering based on 36 overlapping differentially expressed probe sets responsive to AF4-MLL
repression in RS4;11 and SEMK2 (light grey), control samples transfected with siAGF1 (dark grey), and pulse
control samples (black). (D) Gene set enrichment analysis (GSEA) of AF4-MLL associated transcription
factors (Gaussmann et al [20]) in AF4-MLL knock-down (‘na_neg’) versus control samples (‘na_pos’). Probe
sets and HGNCGene Symbols are listed in S8 and S9 Tables.
doi:10.1371/journal.pone.0120326.g005
MLL Fusion Knockdown Gene Expression Profiling
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(Fig. 6B, upper panel). As a control we also analyzed enrichment of genes responsive to AF4-
MLL knock-down in ourMLL-AF4 knock-down signature, and found no significant enrich-
ment (p = 0.55) (Fig. 6B, lower panel).
Genes up-regulated after MLL fusion knock-down are enriched for
hypermethylated promoter regions
Interestingly, while several knownMLL-AF4 target genes were down-regulated after the loss of
theMLL fusion, a substantial proportion of genes in ourMLL fusion knock-down signature
were up-regulated (Fig. 2). Per definition these genes are not directly regulated by the MLL fu-
sion protein via H3K79 mediated transcription activation. Therefore, we explored an alterna-
tive mechanism of transcriptional regulation. We recently demonstrated thatMLL-rearranged
infant ALL is characterized by severe aberrant DNA hypermethylation, leading to transcrip-
tional silencing of numerous genes. [10] Using 165 probe sets associated with gene promoter
methylation in the majority ofMLL-rearranged infant ALL patients, we applied GSEA on our
MLL fusion knock-down signatures. GSEA demonstrated significant enrichment of these
genes among the genes up-regulated after knock-down ofMLL-AF4 andMLL-ENL
(NES = 1.36, p = 0.03; leading edge in S13 Table) (Fig. 7). These data suggest that there is an ac-
tive interplay between MLL fusion proteins and DNAmethylation patterns inMLL-rearranged
ALL cells.
Discussion
The here identified genes which are transcriptionally responsive to the repression of MLL-AF4
and MLL-ENL represent a rich source of potential therapeutic targets forMLL-rearranged
acute leukemia. Apart from gene signatures associated with the loss of MLL-AF4 and
MLL-ENL, we also identified genes responsive to the repression of AF4-MLL. As it has been
suggested that the AF4-MLL oncogene could be indispensable for the initiation of t(4;11)+ leu-
kemias, our gene signatures associated with the presence and loss of AF4-MLLmay well pro-
vide novel insights into the biology of this leukemia. Apart from genes down-regulated upon
the loss ofMLL fusions, we also identified a substantial number of genes which were up-regu-
lated in response toMLL fusion repression. Although MLL fusion proteins activate a variety of
target genes (represented in the datasets of Guenther [7, 8] and Krivtsov [7, 8]) by the recruit-
ment of DOT1L and subsequent methylation of H3K79 [7, 8], these data suggest that the MLL
fusion itself and/or its activated target genes also actively repress and activate other genes via al-
ternative mechanisms. For instance, we found significant enrichment of the genes activated
after knock-down of theMLL fusions in our previously published gene signatures associated
with promoter hypermethylation in t(4;11)+ and t(11;19)+ infant ALL samples. [10] This un-
derscores the importance of the role of DNA methylation inMLL-rearranged infant ALL, as it
appears, to some extent, to be influenced by the presence of the MLL fusion.
Yet, the data presented here should be interpreted with caution as we were not able achieve
complete repression of theMLL fusions, which may have affected the results. On the other
hand, a full knock-down of theMLL fusion may not have provided better data per se, as that
Fig 6. Genes responsive to AF4-MLL repression characterize AF4-MLL expressing (4;11)+ infant ALL
patients. (A) Heatmap visualization and hierarchical clustering of primary t(4;11)+ infant ALL samples
exhibiting AF4-MLL expression (n = 15, red), or lacking AF4-MLL expression (n = 11, blue), based on the top
50 most differentially expressed genes between both patient groups. Up-regulated genes are depicted in red,
down-regulated genes are depicted in blue. (B) Gene set enrichment analysis (GSEA) of AF4-MLL (upper
panel) and MLL-AF4 (lower panel) target genes in AF4-MLL positive patients (‘1’) versus AF4-MLL negative t
(4;11) patients (‘0’). Probe sets and HGNCGene Symbols are listed in S10 and S11 Tables.
doi:10.1371/journal.pone.0120326.g006
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may have generated more non-specific effects due to enhanced apoptosis induced by the loss of
MLL-AF4. [13, 17] Other points of concern may be the slight down-regulation of wild-type
AF4 in SEMK2 cells transfected with siRNAs againstMLL-AF4, as well as the fact that siRNAs
directed against AF4-MLL also affected wild-typeMLL expression. A possible explanation for
this phenomenon is thatMLL and AF4 are downstream effectors of the fusion protein. Howev-
er, we confirmed significant enrichment of differentially regulated genes upon repression of
the different MLL fusions in recently published gene signatures consisting of MLL-AF4 target
genes (7,8), and a gene signature associated with the loss of AF4-MLL. (17) Moreover, we also
demonstrate that our identified genes accurately characterizeMLL-rearranged ALL patient
samples. Furthermore, Ingenuity pathway analysis (IPA) suggested that potential regulators of
our gene signature consisting of genes transcriptionally responsive to the knock-down of MLL
fusion genes, involve several miRNAs that supposedly target eitherMLL (i.e. KMT2A) and/or
AF4 (i.e. AFF1). This again implies that our gene signatures indeed consist of genes controlled
by MLL fusion proteins. Therefore we believe that the obtained data is valid and informative,
despite the limited levels of knock-down and the induced suppression of either AF4 or MLL.
Among the here observed genes that are down-regulated after knockdown of the MLL fu-
sions we found several genes that potentially play important roles in leukemia maintenance
and/or leukemogenesis. For instance, cyclin-dependent kinase 6 (CDK6), which was identified
Fig 7. Genes up-regulated in response toMLL-AF4 andMLL-ENL repression include genes normally
silenced by promoter methylation inMLL-rearranged infant ALL.Gene set enrichment analysis (GSEA)
of hypermethylated promoter regions in t(4;11) and t(11;19) patients (Stumpel et al [10]) inMLL fusion
positive (‘na_pos’) versusMLL fusion negative (‘na_neg’) samples.
doi:10.1371/journal.pone.0120326.g007
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as one of theMLL fusion target genes, as the genomic region encompassing CDK6 revealed en-
hanced occupancy of both MLL-AF4 and H3K79 dimethylation.[8] We recently reported data
showing the important role of CDK6 in the proliferation ofMLL-rearranged ALL cells, demon-
strating experimentally that inhibition of CDK6 readily induces impairment of leukemic cell
proliferation. [21] Other genes in our core signature of genes transcriptionally responsive to
the loss of MLL fusion expression are potentially important in leukemogenesis. For example,
high expression of the Ets family transcription factor ERG, which is down-regulated after MLL
fusion knock-down, is associated with a poor clinical outcome in both acute myeloid leukemia
(AML) and T-cell acute lymphoblastic leukemia (T-ALL). [22, 23] Moreover, enforced ERG
expression induces both T-ALL and AML in murine models [24, 25], suggesting that ERG con-
tributes to leukemia development. As the inhibition of ERG could possibly benefit the survival
ofMLL-rearranged ALL patients as well as patients suffering from AML and T-ALL, this gene
represents an interesting candidate target gene for therapeutic intervention. More genes that
are down-regulated after knockdown of the MLL fusions, and that have been associated with
oncogenesis include SATB1 [26–28], KAT7 [29–31], ADA [32], PPM1F [33, 34], and HOXA7
[35].
Likewise, potential therapeutic targets can also be found among genes that are up-regulated
upon knock-down of the MLL fusions. Among these genes we found regulator of G-protein
signaling protein-2 (RGS2), which has been demonstrated to contribute to myeloid differentia-
tion and its repression is considered to be an important event in leukemic transformation of
FLT3-ITD+ AML. [36] Moreover, RGS2 functions as a tumor suppressor in various human
cancers. [37–39] Hypothetically, induction of this protein may suppressMLL-rearranged
ALL progression.
In conclusion, we strongly believe that the genes identified in the present study represent
genes which directly and readily respond to the loss of the MLL-AF4, MLL-ENL, or AF4-MLL,
and that these genes potentially include attractive therapeutic targets and provide important in-
sights into the biology underlyingMLL-rearranged acute leukemias.
Supporting Information
S1 File. Materials and Methods.
(DOCX)
S1 Table. Differentially expressed genes in response to the repression of MLL-AF4 and
MLL-ENL as compared to the siAGF1 control or the pulse control.
(DOCX)
S2 Table. Differentially expressed genes in response to the repression of MLL-AF4 and
MLL-ENL as compared to the siAGF1 control and the pulse control combined.
(DOCX)
S3 Table. Leading edge of GSEA comparing MLL-fusion knockdown samples versus control
samples using MLL-AF4 target genes dataset from Guenther et al.
(DOCX)
S4 Table. Leading edge of GSEA comparing MLL-fusion knockdown samples versus control
samples using MLL-AF4 target genes from Krivtsov et al.
(DOCX)
S5 Table. Differentially lower expressed genes in response to the repression of MLL-AF4
and MLL-ENL as compared to the siAGF1 control and the pulse control combined.
(DOCX)
MLL Fusion Knockdown Gene Expression Profiling
PLOS ONE | DOI:10.1371/journal.pone.0120326 March 20, 2015 13 / 16
S6 Table. Leading edge of GSEA comparingMLL-rearranged patients versus wild-type
MLL patients using 57 MLL-AF4 target gene probe sets.
(DOCX)
S7 Table. Upstream regulators of the differentially lower expressed genes in response to the
repression of MLL-AF4 and MLL-ENL.
(DOCX)
S8 Table. Differentially expressed genes in response to the repression of MLL-AF4 and
MLL-ENL as compared to the siAGF1 control or the pulse control.
(DOCX)
S9 Table. Differentially expressed genes in response to the repression of MLL-AF4 and
MLL-ENL as compared to the siAGF1 control and the pulse control combined.
(DOCX)
S10 Table. Down-regulated genes in AF4-MLL signature.
(DOCX)
S11 Table. Down-regulated genes inMLL-AF4 signature.
(DOCX)
S12 Table. Leading edge of GSEA comparing AF4-MLL positive patients versus AF4-MLL
negative t(4;11) patients using 58 AF4-MLL target gene probe sets.
(DOCX)
S13 Table. Leading edge of GSEA comparing MLL fusion knockdown versus control sam-
ples using dataset from Stumpel et al.
(DOCX)
Acknowledgments
The authors would like to thank Dr. Olaf Heidenreich for critically reviewing the manuscript.
We thank the members and participating institutes of the INTERFANT study for generously
providing leukemic samples. M.H.v.d.L. is a PhD candidate at the Erasmus University and this
work is submitted in partial fulfillment of the requirement for the PhD. This research was
funded by KIKA (Stichting Kinderen Kankervrij), and R.W.S. was financially supported by
KWF Kankerbestrijding (Dutch Cancer Society).
Author Contributions
Conceived and designed the experiments: MHvdL RP RWS. Performed the experiments:
MHvdL LS PS EMCD PGC DS JdB OW. Analyzed the data: MHvdL EvR. Wrote the paper:
MHvdL RP RWS.
References
1. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia. 1996 Feb; 10(2):372–7.
PMID: 8637251. Epub 1996/02/01. eng.
2. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for in-
fants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study
and a multicentre randomised trial. Lancet. 2007 Jul 21; 370(9583):240–50. PMID: 17658395. Epub
2007/07/31. eng.
3. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New insights to the MLL recombi-
nome of acute leukemias. Leukemia. 2009 Aug; 23(8):1490–9. PMID: 19262598. Epub 2009/03/06.
eng. doi: 10.1038/leu.2009.33
MLL Fusion Knockdown Gene Expression Profiling
PLOS ONE | DOI:10.1371/journal.pone.0120326 March 20, 2015 14 / 16
4. Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A, et al. Immu-
nobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of
MLL gene rearrangement. Leukemia. 2007 Apr; 21(4):633–41. PMID: 17268512. Epub 2007/02/03.
eng.
5. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, et al. MLL transloca-
tions specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002
Jan; 30(1):41–7. PMID: 11731795. Epub 2001/12/04. eng.
6. Yeoh EJ, Ross ME, Shurtleff SA, WilliamsWK, Patel D, Mahfouz R, et al. Classification, subtype dis-
covery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profil-
ing. Cancer Cell. 2002 Mar; 1(2):133–43. PMID: 12086872. Epub 2002/06/28. eng.
7. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles de-
fine murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 4; 14(5):355–68. PMID:
18977325. Pubmed Central PMCID: 2591932. Epub 2008/11/04. eng. doi: 10.1016/j.ccr.2008.10.001
8. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant chroma-
tin at genes encoding stem cell regulators in humanmixed-lineage leukemia. Genes & development.
2008 Dec 15; 22(24):3403–8. PMID: 19141473. Pubmed Central PMCID: 2607073. Epub 2009/01/15.
eng.
9. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 is a key target in t(4;11) leu-
kemias that contributes to gene activation through an AF4-MLL complex interaction. Cell reports. 2013
Jan 31; 3(1):116–27. PMID: 23352661. Pubmed Central PMCID: 3607232. doi: 10.1016/j.celrep.2012.
12.016
10. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, et al. Specific promoter
methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influ-
ences clinical outcome, and provides therapeutic options. Blood. 2009 Dec 24; 114(27):5490–8. PMID:
19855078. Epub 2009/10/27. eng. doi: 10.1182/blood-2009-06-227660
11. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, et al. Promoter hypermethylation in
MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 2010 Jun 10; 115
(23):4798–809. PMID: 20215641. Pubmed Central PMCID: 2890186. Epub 2010/03/11. eng. doi: 10.
1182/blood-2009-09-243634
12. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T, et al. The AF4.MLL fusion
protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010 Apr 29; 115
(17):3570–9. PMID: 20194896. Epub 2010/03/03. eng. doi: 10.1182/blood-2009-06-229542
13. Kumar AR, Yao Q, Li Q, Sam TA, Kersey JH. t(4;11) leukemias display addiction to MLL-AF4 but not to
AF4-MLL. Leuk Res. 2011 Mar; 35(3):305–9. PMID: 20869771. Pubmed Central PMCID: 3011030.
Epub 2010/09/28. eng. doi: 10.1016/j.leukres.2010.08.011
14. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t
(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985 Jan;
65(1):21–31. PMID: 3917311.
15. Pocock CF, Malone M, Booth M, Evans M, Morgan G, Greil J, et al. BCL-2 expression by leukaemic
blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translo-
cation. Br J Haematol. 1995 Aug; 90(4):855–67. PMID: 7669664.
16. Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the
study of MLL gene alterations. Leukemia. 2004 Feb; 18(2):227–32. PMID: 14671638.
17. Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O. Targeting MLL-AF4 with
short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
Blood. 2005 Nov 15; 106(10):3559–66. PMID: 16046533. Epub 2005/07/28. eng.
18. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, et al. AML1/MTG8 oncogene suppres-
sion by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood.
2003 Apr 15; 101(8):3157–63. PMID: 12480707. Epub 2002/12/14. eng.
19. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX, et al. Gene
expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leu-
kemia in infants. Blood. 2010 Apr 8; 115(14):2835–44. PMID: 20032505. Epub 2009/12/25. eng. doi:
10.1182/blood-2009-07-233049
20. Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I, et al. Combined effects of the two re-
ciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling ca-
pacity and growth transformation. Oncogene. 2007 May 17; 26(23):3352–63. PMID: 17130830. Epub
2006/11/30. eng.
21. van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R, et al. MLL fusion-driven
activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell cycle. 2014 Mar 1; 13
(5):834–44. PMID: 24736461. Pubmed Central PMCID: 3979919. doi: 10.4161/cc.27757
MLL Fusion Knockdown Gene Expression Profiling
PLOS ONE | DOI:10.1371/journal.pone.0120326 March 20, 2015 15 / 16
22. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K, Whitman SP, et al. Overexpression of
the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyo-
type: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234–42. PMID:
16275934.
23. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, et al. High expression lev-
els of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classifi-
cation of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J
Clin Oncol. 2007 Aug 1; 25(22):3337–43. PMID: 17577018.
24. Thoms JA, Birger Y, Foster S, Knezevic K, Kirschenbaum Y, Chandrakanthan V, et al. ERG promotes
T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell en-
hancer. Blood. 2011 Jun 30; 117(26):7079–89. PMID: 21536859. doi: 10.1182/blood-2010-12-317990
25. Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schutte J, et al. Genome-scale expression
and transcription factor binding profiles reveal therapeutic targets in transgenic ERGmyeloid leukemia.
Blood. 2013 Oct 10; 122(15):2694–703. PMID: 23974202. Pubmed Central PMCID: 3795462. doi: 10.
1182/blood-2013-01-477133
26. Zhang Y, Tian X, Ji H, Guan X, XuW, Dong B, et al. Expression of SATB1 promotes the growth and me-
tastasis of colorectal cancer. PloS one. 2014; 9(6):e100413. PMID: 24971456. Pubmed Central
PMCID: 4074063. doi: 10.1371/journal.pone.0100413
27. Niu Y, Wang L, Cheng C, Du C, Lu X, Wang G, et al. Increased expressions of SATB1 and S100A4 are
associated with poor prognosis in human colorectal carcinoma. APMIS: acta pathologica, microbiolo-
gica, et immunologica Scandinavica. 2014 Sep 25. PMID: 25257341.
28. Zhang L, Cheng F, He R, Chen H, Liu Y, Sun J. Inhibition of SATB1 by shRNA suppresses the prolifera-
tion of cutaneous malignant melanoma. Cancer biotherapy & radiopharmaceuticals. 2014 Mar; 29
(2):77–82. PMID: 24392879. Pubmed Central PMCID: 3929234.
29. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic path-
ways associated with breast cancer subtypes. Molecular cancer research: MCR. 2009 Apr; 7(4):511–
22. PMID: 19372580. doi: 10.1158/1541-7786.MCR-08-0107
30. Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, et al. Hbo1 is a cyclin E/CDK2 substrate
that enriches breast cancer stem-like cells. Cancer research. 2013 Sep 1; 73(17):5556–68. PMID:
23955388. Pubmed Central PMCID: 3773499. doi: 10.1158/0008-5472.CAN-13-0013
31. Iizuka M, Susa T, Takahashi Y, Tamamori-Adachi M, Kajitani T, Okinaga H, et al. Histone acetyltrans-
ferase Hbo1 destabilizes estrogen receptor alpha by ubiquitination and modulates proliferation of
breast cancers. Cancer science. 2013 Dec; 104(12):1647–55. PMID: 24125069. doi: 10.1111/cas.
12303
32. Morisaki T, Fujii H, Miwa S. Adenosine deaminase (ADA) in leukemia: clinical value of plasma ADA ac-
tivity and characterization of leukemic cell ADA. American journal of hematology. 1985 May; 19(1):37–
45. PMID: 3985005.
33. Susila A, Chan H, Loh AX, Phang HQ,Wong ET, Tergaonkar V, et al. The POPX2 phosphatase regu-
lates cancer cell motility and invasiveness. Cell cycle. 2010 Jan 1; 9(1):179–87. PMID: 20016286.
34. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, et al. MicroRNA-200c re-
presses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and
PPM1F. Mol Cell Biol. 2012 Feb; 32(3):633–51. PMID: 22144583. Pubmed Central PMCID: 3266604.
doi: 10.1128/MCB.06212-11
35. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on
Hoxa7 and Hoxa9. Genes & development. 2003 Sep 15; 17(18):2298–307. PMID: 12952893. Pubmed
Central PMCID: 196466.
36. Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, et al. RGS2 is an important tar-
get gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transforma-
tion. Blood. 2005 Mar 1; 105(5):2107–14. PMID: 15536149.
37. Ying L, Lin J, Qiu F, Cao M, Chen H, Liu Z, et al. Epigenetic repression of RGS2 by UHRF1 promotes
bladder cancer progression. The FEBS journal. 2014 Oct 16. PubMed PMID: 25323766.
38. Lyu JH, Park DW, Huang B, Kang SH, Lee SJ, Lee C, et al. RGS2 suppresses breast cancer cell growth
via a MCPIP1-dependent pathway. Journal of cellular biochemistry. 2014 Sep 4. PubMed PMID:
25187114.
39. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, et al. Regulator of G-protein signaling 2 (RGS2) inhib-
its androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2006
Jun 22; 25(26):3719–34. PMID: 16449965.
MLL Fusion Knockdown Gene Expression Profiling
PLOS ONE | DOI:10.1371/journal.pone.0120326 March 20, 2015 16 / 16
